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Abstract: Interstitial cystitis/bladder pain syndrome (IC/BPS) and vulvodynia are chronic pain syndromes
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Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is
a chronic multifaceted illness whose clinical hallmarks
include perceived bladder pain and irritative voiding
symptoms, in the absence of easily identifiable pathology.
Similarly, vulvodynia is a broad term imparted to varied
forms of persistent vulvar pain of unknown origin. Once
thought to be rare clinical entities, recent epidemiology
suggests that these conditions are not only rather common,
but also frequently co-exist. Furthermore, IC/BPS and
vulvodynia often share co-morbidities. The apparent close
clinical association between these syndromes may relate
to similar embryological origins and/or multiple forms of
shared pathologies. This article will examine the similarities
between these conditions and therapeutic implications.
Common embryological derivations
Urogenital tissues share common embryological origins,
which may account for the frequent coexistence of IC/BPS
and vulvodynia (Figure 1). McCormack first reported on
36 patients with focal vulvitis (vulvodynia) of those, 11 also
had comorbid IC/BPS (1). Fitzpatrick et al. then published
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case reports of three women with coexisting IC/BPS and
vulvodynia and discussed the significance of a disorder
of the urogenital sinus (UGS)-derived epithelium for
both diagnosis and treatment (2). Similar embryological
derivations between tissues may also account for common
complaints of urethral pain (a region that bridges the
bladder and genital tissue) in both patient groups.
Indeed, urogenital tissues are of endodermal origin
and derived from the cloacal membrane, a structure that
is formed at the third fetal week. By the seventh week,
a urorectal septum divides the cloacal membrane, thus
separating it into an anterior urogenital and a posterior
anal membrane (3). The urogenital membrane perforates to
create the primary UGS, a structure that communicates with
the amniotic cavity. A definitive UGS is formed with further
partitioning that includes caudal phallic and pelvic regions.
These regions will ultimately develop into the vaginal
introitus and the female urethra/lower portion of vagina,
respectively. The uterus, cervix, and upper portion of the
vagina are derived from the Müllerian ducts (mesodermal
tissue) after the ducts fuse and canalize with the UGS.
Other endodermal derivatives of clinical importance are the
Skene’s and Bartholin’s glands. “Hart’s line” found on the
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Figure 1 Endodermal derivation of the urogenital system
highlighted in yellow. (A) The descent of the urogenital septum
(or fold) at week 7. Note the intact cloacal membrane formed by
the juxtaposition of ectodermal and endodermal elements; (B)
breakdown of the cloacal membrane between weeks 8-9 and the
final division between the rectum and urogenital system; (C) final
differentiation of endodermal structures at 12 weeks.
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Over the past two decades, much basic research has been
invested to defining the cause of both pain syndromes.
Although lines of investigation for these conditions differ in
many aspects, there are some commonalities of pathology
that have been identified.
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Figure 2 Endodermal derivatives on physical examination of adult

Ty p i c a l l y, m a s t c e l l s a r e a s s o c i a t e d w i t h a l l e r g i c
disorders and acute inflammatory responses, secreting
numerous proinflammatory mediators; contributing to
a variety of chronic inflammatory conditions such as
intestinal ulceration, rheumatoid arthritis and Crohn’s
disease. Additionally, they are found in stress-induced
neuroinflammatory diseases including multiple sclerosis,
migraines, atopic dermatitis, chronic urticaria, irritable
bowel syndrome and IC/BPS (5). Vasoactive, nociceptive
and proinflammatory molecules released from activated
mast cells produce neuronal sensitization and secretion of
neurotransmitters that further stimulate mast cells. It is this
cycle that may contribute to the chronic voiding and pain
symptoms associated with IC/BPS (6).
Similarly, enhanced mast cell activity has been identified
in vulvodynia patients where histamine release is thought to
stimulate peripheral pain transmitting neurons (C and A-δ
fibers) (7-9). Borenstein et al. compared vestibular tissue
from women with severe vulvodynia (n=40) for mast cell
count and degranulation and nerve cell total area compared
to controls (n=7). They found a significant increase in the
total mast cell count (P=0.006; P=0.15) and degranulated
mast cells (P=0.0001) in the vulvodynia patients compared
to controls. The total nerve fiber area was found to be
10 times higher in the vulvodynia group (4,190 μm 2 )
compared to the control group (425 μm2) (P=0.01) (10).

in blue.

Neurogenic inflammation, neuropathic pain, central
sensitization

inner aspect of the labia minor marks the final boundary
between endodermal (UGS) and ectodermal derivatives
(Figure 2). The upper portion of the UGS develops into
the urinary bladder. Past embryological dogma suggested
that the trigone of the bladder was derived from mesoderm;
however, more recent investigations suggest that the entire
bladder is of endodermal origin (4).

The role of the peripheral and central nervous systems in
the pathogenesis of IC/BPS and vulvodynia is complex and
profoundly incomplete. Clinical observations suggest that
both of these pain syndromes have subtypes where pain
is derived from the “end organ” and/or those where pain
is generated at higher levels within the nervous system.
Traditionally, treatment for these patients has been targeted
to peripheral pathology; however, these therapies may be

are highlighted in yellow. Ectodermal derivatives are highlighted
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insufficient due to altered central nervous system (CNS)
processing.
From a neuroanatomical perspective, the female urinary
and reproductive systems are innervated by the same sacral
nerve pathways (11). This nerve innervation is responsible
for both the motor/efferent and sensory/afferent pathways
of the somatic and visceral systems (12). Additionally, the
dorsal root ganglion cells at the thoracolumbar and sacral
levels play a role in the transmission of painful sensations
from the pelvis to the brain (13).
Much of the pain experienced by IC/BPS and vulvodynia
patients appears to be neuropathic. Neuropathic pain is a
primary excitatory disorder of the nervous system occurring
through a variety of mechanisms such as infection, trauma,
or with no apparent etiology. In patients with neuropathic
pain, the injured nerve fibers fire spontaneously or at
a lower threshold, the latter phenomenon accounting
for the local allodynia (painful response to non-noxious
stimuli) identified in many patients with IC/BPS and
vulvodynia. Neurogenic inflammatory events may be
part of this process whereby primary afferent nociceptors
(primarily C-fibers but to a lesser extent also A-δ fibers)
are stimulated with the subsequent release of inflammation
provoking neuropeptides [e.g., substance P, calcitonin generelated peptide (CGRP), neurokinin A and B] and lead to
a state of neurologic “wind-up” (6,8,13,14). Downstream
clinical events typically include local vasodilation, edema,
hyperalgesia and allodynia; all notable characteristics in
certain subgroups of IC/BPS and vulvodynia. Neurogenic
inflammation plays a role in local pain and inflammation,
but also at referred sites (6,13). This may explain why
patients with IC/BPS may experience referred pain in the
vulva and patients with vulvodynia may experience referred
pain in the bladder and urethra.
Abnormal pain processing, suggesting CNS sensitization,
has been identified in IC/BPS and vulvodynia patients.
Ness et al. demonstrated generalized lower thermal pain
tolerances in IC/BPS patients than healthy controls (15).
Previous studies in vulvodynia showed lower peripheral
pain thresholds in both painful and non-painful areas when
compared to healthy controls. (16-18).
Central processing abnormalities in vulvodynia were
further investigated by functional MRI (fMRI). This revealed
that when women afflicted with vulvodynia described
pressure as painful, they had significantly higher activation
levels in the insular and frontal cortical regions than did
the healthy control group (19). Hampson et al. recently
compared local (vulvar) and remote (thumb) pressure-
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evoked pain processing via fMRI scans between women
with vulvodynia (n=24), age-matched healthy controls
(n=13), and positive controls with fibromyalgia (n=24)
(for thumb pressure). Vulvodynia and fibromyalgia patients
displayed similar insular brain activations that were greater
than the healthy control patients in response to thumb
pressure (P<0.005). Also, compared to the healthy controls,
the vulvodynia group displayed greater levels of activation
within the insula, dorsal mid cingulate, posterior cingulate
and thalamus during thumb pressure (P<0.005) (20).
Grey matter densities in areas that modulate pain and
stress (e.g., parahippocampal gyrus, hippocampus and basal
ganglia) were significantly higher in women with vulvodynia
vs. controls (21).
Recent fMRI studies in IC/BPS demonstrated alterations
in resting state oscillations and enhanced connectivity in
sensory and motor networks in IC/BPS patients compared
to controls. Increased connectivity was greatest in patients
reporting pain during bladder filling (22). White matter
abnormalities, many of which correlated to pelvic pain severity
and urinary symptoms, were detected in female IC/BPS
patients using diffusion tensor imaging or fractional
anisotropy (23).
Hormonal influences
Endocrine dysregulation has been postulated to account
for the development and/or maintenance of IC/BPS
and vulvodynia. Symptom flares in these patients may in
fact be modulated by the estrogen surge before menses
that induces the release of histamine from mast cells
resulting in increased amounts of substance P (24,25).
A neuromodulatory role of estrogen on pain transmission
at various sites has been documented (26). Gonadal
hormones are also theorized to influence the CNS activity
of neuromodulators involved in nociceptive processing (27).
Clinically, this may impact patients with both IC/BPS
and vulvodynia. A recent prospective study investigated
the effect of local (topical) estrogen on urinary and sexual
symptoms in premenopausal women with IC/BPS (28).
A total of 34 women with IC/BPS were treated with topical
estriol 3 times per week for 12 weeks. A total of 94.1% (32/34
of the women) were diagnosed with concomitant vulvodynia.
Results indicate a significant improvement of both urinary
symptoms and sexual function (P<0.001, for both).
Investigators theorize that women with these conditions
are vulnerable to changes in sex steroid milieu thereby
predisposing urogenital tissues to abnormal responses (28).
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Many IC/BPS patients report symptom exacerbation, or
flares, perimenstually or around ovulation. Powell-Boone et al.
conducted a small study on IC/BPS patients and healthy
controls that showed a correlation between pain and urinary
frequency scores and the phases of the menstrual cycle (29).
Several studies have shown a link between combined
hormonal oral contraception and vulvodynia (30-32);
however, other studies failed to demonstrate this correlation
(33,34). Further investigations are warranted to determine
the association between endogenous and exogenous gonadal
hormones and the development and/or exacerbation of
IC/BPS and vulvodynia.
Epidemiology
Epidemiology with regard to IC/BPS and vulvodynia has
been primarily hampered by the varied definitions for these
syndromes. Nevertheless, most investigations indicate
that these conditions not only have a high prevalence and
have common co-morbidities; but that they are frequently
identified in the same patient.
Among women age 18 and over in the US, recent data
suggest between 3.3 and 7.9 million women have symptoms
of IC/BPS (35). The prevalence of vulvodynia has been
estimated to range between 4-16%, effecting more than
2.4 million women in the US (36-38). The association between
IC/BPS and vulvodynia is often reported, with 25% of women
with IC/BPS also reporting to have vulvodynia (28,37,39,40).
Gordon et al. conducted an Internet-based survey of
428 women with self-reported vulvar pain and found that
11% had an IC/BPS diagnosis (41). Nguyen et al. conducted a
survey of 1,457 women with diagnosed vulvodynia [generalized
(involves entire vulva) n=467, localized (involves a specific
portion or component of the vulva) n=639, or both n=351] and
the presence of co-morbid pain conditions. They found that
18.8% of the generalized group, 14.7% of the localized group,
and 27.9% of the group with both types of vulvodynia also
reported co-morbid IC/BPS (P<0.001) (42).
Patients often have overlapping symptoms making
diagnosis of one or both conditions all the more difficult.
Frequency of both conditions is often underestimated due
to the fact that many in the medical community believe
these conditions to be psychological in origin or because
women reluctant to discuss their symptoms (43).
Comorbid conditions
IC/BPS and vulvodynia are frequently associated with
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other pain syndromes. Interestingly, recent non-population
based studies suggest that irritable bowel syndrome
and fibromyalgia are the two most prevalent comorbid
conditions associated with both conditions. (42,44). Other
co-morbid conditions commonly seen in both IC/BPS and
vulvodynia are temporal mandibular joint and muscle disease
(TMD) and chronic fatigue syndrome (CFS). As previously
mentioned, IC/BPS and vulvodynia are frequently
seen as co-morbid to each other. Both Nickel et al.
and Nguyen et al. indicate that the prevalence of multiple
comorbidities increases with symptom severity (42,44).
Hypertonic pelvic floor dysfunction (HTPFD) is
commonly seen in both conditions. Many patients with
IC/BPS and vulvodynia present with muscle tenderness,
myofascial pain, spasticity, voiding dysfunction and
dyspareunia which are also manifestations of HTPFD.
Approximately 50-87% of patients with IC/BPS are
diagnosed with HTPFD (45). Yong et al. recently reported
the prevalence of PFD (defined as pelvic floor muscle
tenderness) in 189 women with chronic pelvic pain
compared to 32 healthy controls. A total of 40% of the
women with chronic pelvic pain (75/189) had concomitant
PFD vs. 13% of controls (4/32) (46). While it is unclear
if HTFPD results from chronic pain of IC/BPS and
vulvodynia or if it is a precipitating factor, HTPFD can
exacerbate symptoms and can itself worsen in response to
IC/BPS or vulvodynia flares.
Quality of life (QOL)
Chronic urogenital pain syndromes may have a profound
effect upon QOL resulting in feelings of hopelessness
and helplessness, depression as well as negatively
impacting personal relationships. A case-controlled
survey demonstrated a correlation between stress, anxiety,
depression and catastrophizing to IC/BPS symptoms and
a decreased QOL (44). Similar reports demonstrate when
compared to controls, women with vulvar pain reported
significantly worse mental health-related QOL, lower levels
of happiness in couple relationships, higher trait anxiety,
increased somatization and catastrophizing related to
dyspareunia (47-49).
Behavioral interventions emphasizing a self-management
approach, such as cognitive behavioral therapy (CBT), are
effective treatment option for both conditions. Numerous
studies have shown that CBT increases perceived control
in patients with chronic pain by reducing pain, helplessness
and psychological distress (50-54). CBT has been shown
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to reduce catastrophizing, decrease pain and improve
sexual functioning in women with vulvodynia and has been
recommended for patients with IC/BPS (55-57).
Sexual function
Sexual dysfunction strongly impacts the QOL in patients
with IC/BPS and vulvodynia. It has been postulated that
pain mediates sexual dysfunction and its associated effects
on QOL. A higher prevalence of moderate to severe
sexual dysfunction has been identified in IC/BPS patients
compared to controls (58,59).
Bogart et al. conducted a telephone survey of women with
IC/BPS (n=1,469) to determine the prevalence of sexual
dysfunction compared to the general population. A total of
88% of the women with a sexual partner reported having
sexual dysfunction vs. 43% in the general population (57).
Gardella et al. evaluated women diagnosed with IC/BPS
(n=47) and a control group (n=47) for the characteristics of
vulvodynia. The prevalence of vulvodynia was 85.1% in the
IC/BPS group compared to 6.4% in controls (P<0.0001).
Dyspareunia was described as “unbearable” in 31.9% of the
IC/BPS group compared to 4.3% of controls (P=0.0001) (39).
Limiting or avoidance of sexual activity due to associated
pain is common in patients with IC/BPS and vulvodynia.
What used to be arousing and satisfying for the couple
may now be a source of pain. Communication, self-care,
changes in sexual scripts and discussion of non-penetrative
alternatives are all important aspects of managing
sexual function with chronic pelvic pain syndromes.
A multidisciplinary approach with urology, physical therapy
and sex therapy is fundamental to targeting the multiple
facets of chronic urogenital pain and altered sexual function.
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expert opinion, some interesting similarities between the
treatments of IC/BPS and vulvodynia can be identified.
These similarities may have potential impact upon
streamlining patient care, particularly for those patients
who suffer from both ailments. Furthermore, similarities
with respect to treatment response may have some bearing
on the underlying pathophysiologies of these conditions.
Behavioral modification
First-line treatment for both IC/BPS and vulvodynia
employs behavioral modification and self-care measures.
Patient empowerment from the initial visit is imperative.
This can be accomplished by giving them information
pertaining to online resources (e.g., medically accurate
websites, advocacy groups), support groups, books, etc.
Stress reduction and relaxation techniques are strongly
recommended. Data suggest that women with urogenital
pain syndromes have higher levels of stress than healthy
controls (60-63). Rothrock et al. conducted a prospective
comparison of 45 IC/BPS patients to 31 age-matched
controls in order to determine how stress levels in daily life
impacts their symptoms. Participants with IC/BPS were
asked to track their daily urinary frequency, urgency, bladder
pain, and stress for 1 month. Results showed that increased
levels of stress were related to greater pain and urgency
in the IC/BPS group, but not in the control group (63).
Clinical observations suggest that stress exacerbates
symptoms and that symptoms tend to worsen stress.
As such, multimodal treatments are suggested for both
conditions to break frequently identified vicious cycles of
pain.
Physical therapy

Clinical implications
Similarities in treatment options
IC/BPS and vulvodynia are complex pain syndromes
accompanied by multiple pain generators, i.e., HTPFD,
where symptom improvement (or lack thereof) rests upon
a gauntlet of trial and error therapies. Unfortunately, there
is a paucity of literature detailing studies for the treatment
of IC/BPS and vulvodynia. Most clinical trials thus far
have been limited to small label open or rare placebocontrolled studies, usually too small to yield useful data (43).
Nonetheless, some useful information has been garnered
from these investigations; and when combined with
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Physical therapy, once rarely used for the treatment of
IC/BPS and vulvodynia, has become a mainstay in the
treatment algorithm. Pelvic floor physical therapy is now
more widely available and effective in the treatment of
both pain syndromes. As previously mentioned, patients
with both IC/BPS and vulvodynia often exhibit pain, taut
bands and/or trigger points in the muscles of the pelvic
floor. Often, patients are found to have involvement of the
external muscles of the pelvis, low back, abdomen and lower
extremities. Physical therapists with a specialized expertise
in chronic urogenital pain employ treatment techniques
including internal and external myofascial release and soft
tissue mobilization in addition to stabilization, stretching
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exercises and biofeedback. It is important to note that there
is no evidence physical therapy strengthening exercises
(Kegel’s) improve symptoms. It has been noted that this
type of pelvic floor therapy may in fact worsen pelvic pain
conditions (64).
Hartmann et al. performed a retrospective review on
women with vulvodynia who were treated with physical
therapy (n=24). They reported that 71% showed greater
than 50% improvement in symptom reduction (65).
Upon interviewing 35 women after completion of a
multimodal physical therapy program, Bergeron et al.,
found that 71% reported complete, great or moderate
improvement (66). A small, prospective study of 13 women
with vulvodynia completed eight sessions of pelvic floor
physical therapy. They demonstrated that physical therapy
led to normalization of pelvic floor muscle tone, significant
reduction in pain during vaginal palpation, and decreased
pain during gynecological exams and sexual intercourse (67).
A large randomized controlled trial (RCT) compared
myofascial physical therapy to global therapeutic massage
in IC/BPS patients (n=81). Participants were randomized
to either group for ten 60-minute sessions over 12 weeks. A
total of 59% of the physical therapy group reported moderate
or marked improvement, compared to 26% in the massage
group on the global response assessment (P=0.0012) (68).
Oral therapies
Many oral therapies prescribed can be used interchangeably
for the treatment of both IC/BPS and vulvodynia.
Tricyclic antidepressants (TCA) are commonly used
in the treatment of many chronic pain conditions with a
neuropathic component. The most common TCAs used in
the treatment of IC/BPS and vulvodynia are amitriptyline
or nortriptyline and are thought to work by: (I) central
and peripheral anticholinergic actions at certain receptor
sites; (II) block reuptake of serotonin and norepinephrine;
(III) block H1-histaminergic receptors thereby inhibiting
mast cell release; (IV) have a sedative effect related to
their antihistaminic properties; (V) desensitizes alpha
two receptors on central noradrenergic neurons; and (VI)
stimulate beta-adrenergic receptors in the bladder (69,70).
Munday et al. reported a 47% complete response to
amitriptyline for the treatment of vulvodynia (n=33),
however, the investigators were also employing behavioral
modification and psychological support (71). Reed et al.
evaluated 162 women prescribed a TCA (amitriptyline,
desiprimine or another tricyclic antidepressant) for vulvodynia.
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Data show at the first follow-up visit at approximately
3 months, 49 of the 83 women taking the TCAs improved by
50%, compared to 30 of the 79 not taking TCAs (improvement
rate =38%, P=0.007). They demonstrated that women taking
TCAs for vulvodynia have greater pain improvement than
women not taking these medications (72).
Hanno and Wein were the first to report a therapeutic
response in an IC/BPS patient being concurrently treated
for depression with amitriptyline (73). Results of a placebocontrolled, double-blind trial of 48 patients with IC/BPS
showed that after 4 months on amitriptyline (25-75 mg,
self-titrating dose), 42% of patients (n=10) on the medication
had a greater than 30% decrease in overall symptom score
compared to 12.5% of those on placebo (n=3) (P<0.001). Pain
and urgency improved in the amitriptyline group compared
to placebo (P<0.001) and 63% (n=15) of the amitriptyline
group reported good or excellent satisfaction with treatment
outcome vs. 4% (n=1) of the placebo group (P<0.001) (74).
Additional investigations have shown similar efficacy of
TCAs for IC/BPS (75-79).
The biggest problem with the use of TCAs in treating
both conditions is the potential adverse effects that
can develop. Some adverse effects that may preclude
continuation with the medication include anticholinergic
effects (constipation, dry mouth, urinary retention), fatigue,
weight gain, sexual dysfunction and cardiac arrhythmias (70).
Anticonvulsants are often employed for the treatment
of IC/BPS and vulvodynia. Anticonvulsants such as
gabapentin, and pregabalin, have been effective in treating
diabetic neuropathy, post herpetic neuralgia and other
diverse pain syndromes of neuropathic origin. The
mechanism of action by which they are thought to improve
pain is through binding to the alpha 2-delta subunit of
voltage-gated of calcium channels thereby decreasing the
release of glutamate, norepinephrine and substance P (80).
Pregabalin has also exhibited anxiolytic effects in RCTs of
generalized anxiety disorder, which may prove beneficial for
patients with chronic urogenital pain conditions (81,82).
Ben-David and Friedman first published efficacy with
using gabapentin for treating women with vulvodynia
(n=17). A total of 82% (n=14) had partial or complete
symptom relief with gabapentin therapy by 2 to 4 weeks of
treatment. Follow-up extended between 26 and 32 weeks
without any reported cases of late failure of therapy (83).
A retrospective chart review of 152 women with vulvodynia
treated with gabapentin by Harris and colleagues showed
98 (64%) had resolution of at least 80% of their symptoms,
and 49 (32%) did not have adequate response. They also
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found that patients with a longer period of untreated illness
seemed to have a less favorable response to therapy (P value
not less than 0.05) (84). Further reports show that gabapentin
improves vulvodynia symptoms either as monotherapy or
as adjuvant therapy (85,86). Currently underway is the first
double-blind, placebo-controlled, crossover study to evaluate
the efficacy of extended release gabapentin, up to 300 mg/day
in the treatment of vulvodynia (87).
The use of gabapentin in the treatment of IC/BPS
is mainly from anecdotal reports. Sasaki et al. evaluated
21 patients with refractory of genitourinary pain, including
eight with interstitial cystitis and two with vulvar pain.
Ten of the 21 patients treated with gabapentin reported
subjective improvement in their symptoms; five of the eight
patients with IC/BPS reported improvement (88).
Antihistamines have been used in the treatment of
IC/BPS for decades. The most common medication used
is hydroxyzine, which can block neuronal activation of
mast cells (89). Sedation is a common side effect with
this medication, so some clinicians have begun to use
montelukast, a leukotriene receptor antagonist. Montelukast
at 10 mg/day has been used in the treatment of both
IC/BPS and vulvodynia with promising results (90,91).
Authors proposed that leukotriene receptor antagonist has
antihistamine action and may modulate the exaggerated
proinflammatory activity.
Conclusions
Many similarities exist between IC/BPS and vulvodynia
including clinical presentation, co-morbid conditions, and
similar responses to medical interventions. Closer examination
reveals commonalities in embryologic origins. Recognition of
possible neuropathic involvement and central sensitization in
conjunction with fMRI changes has far-reaching implications
for improving treatment options. Further research is needed
to determine whether these conditions are manifestations of a
more global chronic urogenital pain syndrome.
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